Satsuma Pharmaceuticals (STSA) Acquired by SNBL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
SNBL to Acquire Satsuma Pharmaceuticals
April 16, 2023 7:41 PM EDTTransaction delivers immediate value and liquidity to Satsuma stockholders
SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share
Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share
With the goal of maximizing value for stockholders, Satsumas Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with SNBL
SOUTH SAN FRANCISCO, Calif., April 16, 2023 (GLOBE NEWSWIRE) --... More
